Therefore, restoration of Sestrin activity or STAT3 inhibition in SESN1&2-deficient cancer cells may be a potential strategy to improve the treatment outcome for patients with cancers bearing mutations in SESN1 or SESN2 genes. This evidence concerns the gene SESN1 and cancer.